Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H24ClNO.ClH |
| Molecular Weight | 366.325 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.ClC1=CC=C(C=C1)C(OCCN2CCCCC2)C3=CC=CC=C3
InChI
InChIKey=UNPLRYRWJLTVAE-UHFFFAOYSA-N
InChI=1S/C20H24ClNO.ClH/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22;/h1,3-4,7-12,20H,2,5-6,13-16H2;1H
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21445282
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21445282
Cloperastine (INN) or cloperastin is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.
CNS Activity
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20460867 |
Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cloperastine rescues impairment of passive avoidance response in mice prenatally exposed to diethylstilbestrol. | 2014-02 |
|
| Cloperastine-based cough syrup and acute dystonic reactions. | 2012-03 |
|
| [Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats]. | 2010-05 |
|
| Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. | 2010-02-05 |
|
| Ameliorating effects of cloperastine on dysfunction of the urinary bladder caused by cerebral infarction in conscious rats. | 2009-11 |
|
| Effects of solid-state reaction between paracetamol and cloperastine hydrochloride on the pharmaceutical properties of their preparations. | 2007-04-20 |
|
| Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry. | 2006 |
|
| Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents. | 2004 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21445282
10–20 mg three times daily for adults
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23047467
Cloperastine inhibited the hERG K⁺ channels, expressed in HEK293 cells, in a concentration-dependent manner with an IC₅₀ value of 0.027 μM
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
239-067-8
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
14984-68-0
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
C95235
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
SUB01367MIG
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
161104
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
PI4N7C63ND
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
100000087974
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
DTXSID5045413
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
PI4N7C63ND
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
C040282
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
CHEMBL415087
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
m3654
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
2104181
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY | |||
|
DBSALT001087
Created by
admin on Mon Mar 31 18:48:52 GMT 2025 , Edited by admin on Mon Mar 31 18:48:52 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD